Effect of Intensive Blood Pressure Control on Cardiovascular Outcomes in Cancer Survivors

作者：Wenjie Li, Zhiyan Wang, Chao Jiang, Chang Hua, Yangyang Tang, Hao Zhang, Xinru Liu, Shiyue Zheng, Yufeng Wang, Mingyang Gao, Qiang Lv, Jianzeng Dong, Changsheng Ma, Xin Du · 发表于：Hypertension · 年份：2024 · DOI：10.1161/hypertensionaha.123.22194 · 被引用次数：7 · 研究领域：Chemotherapy-induced cardiotoxicity and mitigation、Pulmonary Hypertension Research and Treatments、Cancer, Lipids, and Metabolism

BACKGROUND: To evaluate whether cancer modifies the effect of intensive blood pressure control on major cardiovascular outcomes. METHODS: Using data of the SPRINT (Systolic Blood Pressure Intervention Trial), we compared the risk of the composite outcomes of myocardial infarction, other acute coronary syndromes, stroke, heart failure, and cardiovascular death in patients with and without a history of cancer. Using Cox proportional hazards regression, we tested interactions between history of cancer and intensive blood pressure control on major cardiovascular outcomes. RESULTS: The study included a total of 9336 patients, with a mean age of 67.9±9.4 years, among whom 2066 (22.2%) were cancer survivors. Over a median follow-up of 3.2 years, 561 primary cardiovascular outcomes were observed. Cancer survivors had a similar risk of experiencing the primary outcome compared with patients without cancer after multivariable adjustment (adjusted hazard ratio, 0.94 [95% CI, 0.77–1.15]). Intensive blood pressure control reduced risk of the primary cardiovascular outcome similarly for cancer survivors (hazard ratio, 0.70 [95% CI, 0.51–0.97]) and patients without cancer (HR, 0.76 [95% CI, 0.63–0.93]; P for interaction 0.74). CONCLUSIONS: In SPRINT study, intensive blood pressure treatment reduced the risk of major cardiovascular events in cancer survivors to a similar extent to that of patients without cancer. Cancer history not requiring active treatment in last 2 years should not be an ...